Sign inJoin waitlistJoin the waitlist

Ernest Camp

Professor and Chief, Division of Surgical Oncology · Baylor College of Medicine

Credentials: · · · · ·

History

Division of Surgical Oncology · Baylor College of Medicine
Present
Dan L Duncan Comprehensive Cancer Center Division · Baylor College of Medicine
Present
Baylor College of Medicine
Present

University of Florida
1997–2004
MS from Medical University of South Carolina
Med Univ of South Carolina Coll of Med
1993–1997
Davidson College
1989–1993

Research

Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines
Clinical Cancer Research · 2006 · 464 citations
Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma
Review · Cancer · 2016 · 226 citations
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells
Cancer Research · 2006 · 222 citations

Lee Ellis
14 papers
Anthony Yang
11 papers · 11 as a resident
Derek Erstad
10 papers
George Van Buren
9 papers · 9 as a resident
Ray Somcio
9 papers
David Cole
7 papers
Kevin O'Carroll
7 papers
William Fisher
7 papers
Christy Chai
6 papers
Nestor Esnaola
6 papers
Eric Kimchi
5 papers
Eric Silberfein
5 papers

Grants

Defining the Role of Tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial Disparities
National Cancer Institute · R01
PI · $2.5M · Ohio State University
2023–2028
Targeting Sphinogsine-1-Phosphate to Overcome SNAI1-Mediated Therapy Resistance in Rectal Cancer
Department of Veterans Affairs · I01
Contact PI · Michael e Debakey Va Medical Center
2019–2024
Innovative Delivery Strategy for CaSm Gene Therapy in Pancreatic Cancer
National Cancer Institute · K08
Contact PI · $867.2K · Medical University of South Carolina
2010–2015

Clinical trials

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Principal investigator · Recruiting · Phase 2
Baylor College of Medicine
2022–2027
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
Sub-investigator · Recruiting · Phase 2
Baylor College of Medicine
2025–2028